Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methylthioribose-1-phosphate isomerase 1 (MRI1) is a protein-coding enzyme involved in the methionine salvage pathway, mediating the reversible interconversion of methylthioribose-1-phosphate and methylthioribulose-1-phosphate[1][6]. Beyond its canonical metabolic role, MRI1 also promotes cell invasion, particularly in melanoma, through protein-protein interaction pathways that are independent of its isomerase activity[1]. Elevated expression is linked to metastatic melanoma, raising possible value in cancer biology, and genetic mutations have been associated with vanishing white matter disease and other neurological syndromes[1]. The enzyme shows identical protein binding activity and contributes to cytoskeletal changes in response to RhoA pathway activation, supporting a dual role in metabolism and cytoskeletal regulation[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methylthioribose-1-phosphate isomerase 1 (MRI1).